Abstract
Dual antiplatelet therapy and drug eluting stents: a marriage of convenience
Highlights
In 1977, a major breakthrough in cardiovascular medicine was introduced by Dr Andreas Gruentzig
In an attempt to fight the exaggerated proliferation after coronary stent implantation, our lab first used rapamycin in an animal model of restenosis showing the effectiveness of this antiproliferative drug in preventing this neointimal proliferation
drug-eluting stents (DES) implantation resulted in a rate of restenosis below 10% [4,5,6], with a similar rate of instent thrombosis. [7,8] It is important to remind that dual antiplatelet therapy was mandatory for at least 3–6 months after DES implantation
Summary
In 1977, a major breakthrough in cardiovascular medicine was introduced by Dr Andreas Gruentzig. The introduction of dual antiplatelet therapy (thyenopiridine on top of aspirin) substantially decreased the rate of stent thrombosis, being currently a rare complication occurring in less than 1% of the procedures.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
